PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30671747-0	2019	Inhibition of Niemann-Pick C1-Like 1 by Ezetimibe Reduces Dietary 5beta,6beta-Epoxycholesterol Absorption in Rats.	Ezetimibe	40-49	NPC1 like intracellular cholesterol transporter 1	Rattus norvegicus	14-36	
28027412-3	2017	Ezetimibe, a selective inhibitor of NPC1L1, is administered for a long time to inhibit cholesterol absorption and there is a possibility that the absorption of alpha-tocopherol is also inhibited by ezetimibe.	Ezetimibe	0-9	NPC1 like intracellular cholesterol transporter 1	Rattus norvegicus	36-42	
29852178-0	2018	Ezetimibe, a NPC1L1 inhibitor, attenuates neuronal apoptosis through AMPK dependent autophagy activation after MCAO in rats.	Ezetimibe	0-9	NPC1 like intracellular cholesterol transporter 1	Rattus norvegicus	13-19	
29852178-2	2018	Ezetimibe (Eze), a Niemann-Pick disease type C1-Like 1 (NPC1L1) pharmacological inhibitor, has been reported to protect hepatocytes from apoptosis via autophagy activation.	Ezetimibe	0-9	NPC1 like intracellular cholesterol transporter 1	Rattus norvegicus	19-54	
29852178-2	2018	Ezetimibe (Eze), a Niemann-Pick disease type C1-Like 1 (NPC1L1) pharmacological inhibitor, has been reported to protect hepatocytes from apoptosis via autophagy activation.	Ezetimibe	0-9	NPC1 like intracellular cholesterol transporter 1	Rattus norvegicus	56-62	
28027412-3	2017	Ezetimibe, a selective inhibitor of NPC1L1, is administered for a long time to inhibit cholesterol absorption and there is a possibility that the absorption of alpha-tocopherol is also inhibited by ezetimibe.	Ezetimibe	198-207	NPC1 like intracellular cholesterol transporter 1	Rattus norvegicus	36-42	
20207946-8	2010	Results from subsequent in situ inhibition studies with ezetimibe, a potent and selective inhibitor of Niemann-Pick C1-like 1 (NPC1L1) transporter, suggested gamma-T3 intestinal uptake is mediated by NPC1L1.	Ezetimibe	56-65	NPC1 like intracellular cholesterol transporter 1	Rattus norvegicus	103-125	
27075173-0	2016	Ezetimibe-sensitive cholesterol uptake by NPC1L1 protein does not require endocytosis.	Ezetimibe	0-9	NPC1 like intracellular cholesterol transporter 1	Rattus norvegicus	42-48	
22528033-4	2012	In situ rat intestinal perfusion with ezetimibe (a NPC1L1 inhibitor) was performed to compare intestinal permeability.	Ezetimibe	38-47	NPC1 like intracellular cholesterol transporter 1	Rattus norvegicus	51-57	
24142910-1	2013	In an effort to develop new molecules with improved antihyperlipidemic activity, eight new 2-azetidinone analogs (4a-4h) of ezetimibe were designed through in silico docking experiments with the crystal structure of the Niemann-Pick C1-like 1 protein (NPC1L1).	Ezetimibe	124-133	NPC1 like intracellular cholesterol transporter 1	Rattus norvegicus	220-250	
24142910-1	2013	In an effort to develop new molecules with improved antihyperlipidemic activity, eight new 2-azetidinone analogs (4a-4h) of ezetimibe were designed through in silico docking experiments with the crystal structure of the Niemann-Pick C1-like 1 protein (NPC1L1).	Ezetimibe	124-133	NPC1 like intracellular cholesterol transporter 1	Rattus norvegicus	252-258	
20207946-8	2010	Results from subsequent in situ inhibition studies with ezetimibe, a potent and selective inhibitor of Niemann-Pick C1-like 1 (NPC1L1) transporter, suggested gamma-T3 intestinal uptake is mediated by NPC1L1.	Ezetimibe	56-65	NPC1 like intracellular cholesterol transporter 1	Rattus norvegicus	127-133	
20207946-8	2010	Results from subsequent in situ inhibition studies with ezetimibe, a potent and selective inhibitor of Niemann-Pick C1-like 1 (NPC1L1) transporter, suggested gamma-T3 intestinal uptake is mediated by NPC1L1.	Ezetimibe	56-65	NPC1 like intracellular cholesterol transporter 1	Rattus norvegicus	200-206	
18022391-2	2007	We hypothesized that ezetimibe, an inhibitor of NPC1L1, improves these metabolic disorders in Zucker obese fatty rats (ZOF).	Ezetimibe	21-30	NPC1 like intracellular cholesterol transporter 1	Rattus norvegicus	48-54	
18403720-3	2008	To investigate this hypothesis, we compared the cellular uptake and inhibitory effects of ezetimibe, the molecular target of which is NPC1L1, between cholesterol and some fat-soluble molecules using rat NPC1L1-overexpressing Caco-2 cells.	Ezetimibe	90-99	NPC1 like intracellular cholesterol transporter 1	Rattus norvegicus	134-140	
17005902-0	2007	In vivo responsiveness to ezetimibe correlates with niemann-pick C1 like-1 (NPC1L1) binding affinity: Comparison of multiple species NPC1L1 orthologs.	Ezetimibe	26-35	NPC1 like intracellular cholesterol transporter 1	Rattus norvegicus	52-74	
17005902-0	2007	In vivo responsiveness to ezetimibe correlates with niemann-pick C1 like-1 (NPC1L1) binding affinity: Comparison of multiple species NPC1L1 orthologs.	Ezetimibe	26-35	NPC1 like intracellular cholesterol transporter 1	Rattus norvegicus	76-82	
17005902-0	2007	In vivo responsiveness to ezetimibe correlates with niemann-pick C1 like-1 (NPC1L1) binding affinity: Comparison of multiple species NPC1L1 orthologs.	Ezetimibe	26-35	NPC1 like intracellular cholesterol transporter 1	Rattus norvegicus	133-139	
34265370-14	2021	Ezetimibe and pemafibrate may promote TICE by increasing Abcg5/g8, while pemafibrate may inhibit intestinal cholesterol absorption by decreasing SR-B1 and NPC1L1.	Ezetimibe	0-9	NPC1 like intracellular cholesterol transporter 1	Rattus norvegicus	155-161